Treating Acute Leukemias in Canada and Latin America

Emerging and Practical Concepts and Controversies in Leukemias

Overview

In recent years, progress in the understanding of acute leukemias has led to novel therapies that are rapidly changing treatment paradigms. Aptitude Health developed the Global Leukemia Academy to help physicians who treat acute leukemias bridge the gap between innovation and implementation for patient care.

Date and Location

April 23–24, 2021, Virtual Meeting

Meeting Content

View the slides and watch the video of Day 1
ALL Plenary Session

View the slides and watch the video of Day 2
Adult Leukemia Session

View slides and watch the video of Day 2
Pediatric ALL Session

Faculty

Elias Jabbour

Elias Jabbour, MD

MD Anderson Cancer Center, USA

Franco Locatelli

Franco Locatelli, MD, PhD

University of Rome
IRCCS Ospedale Pediatrico Bambino Gesù, Italy

Lia Gore

Lia Gore, MD

University of Colorado,
Anschutz Medical Campus, USA

Roberta Demichelis

Roberta Demichelis, MD

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico

Josep Ribera

Josep Ribera, MD

Catalan Institute of Oncology, University Hospital Germans Trias i Pujol, Spain

Andre Schuh

Andre Schuh, MD

Princess Margaret Cancer Centre, Canada

Naval Daver

Naval Daver, MD

MD Anderson Cancer Center (MDACC), Houston, TX

Agenda

This 2-day interactive virtual meeting with global experts will focus on the management of acute leukemias in adult, young adult, and pediatric patients in various countries within the Latin America and Canadian regions.

Day 1: Follow presentations, interact in panel discussions, and debate about novel approved therapies, evolving treatment paradigms, and other hot topics, including patient management during the COVID-19 pandemic.

Day 2: Join the pediatric or adult breakout session to learn about treatment strategies for newly diagnosed and relapsed leukemia patients and attend the patient case-based panel discussion about toxicity management.

Day 1 – PLENARY SESSIONS Friday, April 23, 2021
Chair: Elias Jabbour, MD

16.00 – 20.00 CDT/GMT-5 (Central Daylight/Mexico City/Bogota Time)
17.00 – 21.00 EDT (Eastern Daylight Time)
18.00 – 22.00 BRT/GMT-3 (Brasilia/Buenos Aires Time)

Rio Time (UTC-3) Topic Presenter
18.00 – 18.10 Welcome and meeting overview; introduction to the voting system Elias Jabbour
18.10 – 18.35 Recent developments in ALL Elias Jabbour
18.35 – 19.00 Review of prognostic value of MRD in ALL José Maria Ribera
19.00 – 19.15 Genetic variants in ALL – Ph+ and Ph-like Andre Schuh
19.15 – 19.30 AYA ALL patients – what is the current treatment approach for this diverse patient population? Lia Gore
19.30 – 19.45 Break  
19.45 – 20.00 Bispecifics as post-reinduction therapy improve survival in high-risk first-relapse AYA B-ALL Franco Locatelli
20.00 – 20.30 Therapeutic approaches in older AML and high-risk AML Naval Daver
20.30 – 21.00 Debate on sequencing CD19-targeted approaches
• Monoclonal antibodies and bispecifics first (10 min)
• CAR T first (10 min)
• Discussion and voting (10 min)

Moderator: Andre Shuh

Elias Jabbour
José Maria Ribera
All faculty

21.00 – 21.50 Leukemia board discussion
• Cases – important details for consideration throughout LATAM
• Regional challenges
• Treatment theory and practical approaches
• Discussion and polling (20 min)
All faculty, Moderator: Elias Jabbour
21.50 – 22.00 Session close Elias Jabbour

Day 2 – BREAKOUT: Saturday, April 24, 2021
Part 1: Adult ALL Patients
Part 2: Adult AML Patients
Chair: Elias Jabbour, MD
Co-chair: Naval Daver, MD

8.00 – 11.30 CDT/GMT-5 (Central Daylight/Mexico City/Bogota Time)
9.00 – 12.30 EDT (Eastern Daylight Time)
10.00 – 13.30 BRT/GMT-3 (Brasilia/Buenos Aires Time)

Rio Time (UTC-3) Topic Presenter
10.00 – 10.15 Session open
• Educational ARS questions for the audience
Elias Jabbour
10.15 – 10.35 Optimizing first-line therapy in adult and older ALL – integration of immunotherapy into frontline regimens
• Presentation (15 min)
• Q&A (5 min)
Elias Jabbour
10.35 – 10.55 Current treatment options for relapsed ALL in adult and elderly patients (including COVID-19 and vaccination strategy)
• Presentation (15 min)
• Q&A (5 min)
José Maria Ribera
10.55 – 11.45 Case-based panel discussion: Management of long- and short-term toxicities and treatment selection in adult and elderly patients
• Panelists: Elias Jabbour, José Maria Ribera, Andre Schuh, Local Experts
Roberta Demichelis
Wellington Fernandes
11.45 – 12.00 BREAK  
12.00 – 12.20 Personalized induction and maintenance approaches for AML
• Presentation (15 min)
• Q&A (5 min)
Naval Daver
12.20 – 12.40 Optimizing management of relapsed/refractory AML
• Presentation (15 min)
• Q&A (5 min)
Expert Speaker
12.40 – 13.15 Case-based panel discussion or questions to the panel on regional challenges in AML care All experts
13.15 – 13.30 Session close
• Educational ARS questions for the audience
Elias Jabbour

Day 2 – BREAKOUT: PEDIATRIC ALL PATIENTS Saturday, April 24, 2021
Chair: Franco Locatelli, MD, PhD

8.00 – 10.30 CDT/GMT-5 (Central Daylight/Mexico City/Bogota Time)
9.00 – 11.30 EDT (Eastern Daylight Time)
10.00 – 12.30 BRT/GMT-3 (Brasilia/Buenos Aires Time)

Rio Time (UTC-3) Topic Presenter
10.00 – 10.15 Session open
• Educational ARS questions for the audience
Franco Locatelli
10.15 – 10.35 First-line treatment of pediatric ALL
• Presentation (15 min)
• Q&A (5 min)
Lia Gore
10.35 – 10.55 Current treatment options for relapsed ALL in children, including HSCT; COVID-19 considerations and vaccinations
• Presentation (15 min)
• Q&A (5 min)
Franco Locatelli
10.55 – 11.15 Bispecifics for pediatric ALL
• Presentation (15 min)
• Q&A (5 min)
Lia Gore
11.15 – 11.45 Case-based panel discussion: Management of long-and short-term toxicities and treatment selection in pediatric patients
• Panelists: María Sara Felice (ARG), Oscar Gonzáles Ramella (MEX), Adriana Seber (BRA), Carlos Andres Portilla (COL)
Luisina Perruzo
Local case presenterAll faculty
11.45 – 12.30 Interactive Q&A and session close
• Educational ARS questions for the audience
Franco Locatelli